Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.94M Sell
53,310
-1,251
-2% -$67.8K 0.8% 35
2025
Q4
$2.68M Sell
54,561
-1,764
-3% -$82.3K 0.75% 35
2025
Q3
$2.43M Sell
56,325
-523
-0.9% -$20.4K 0.72% 39
2025
Q2
$2.18M Buy
56,848
+1,971
+4% +$75.3K 0.67% 40
2025
Q1
$2.13M Buy
54,877
+22,220
+68% +$813K 0.71% 39
2024
Q4
$1.1M Buy
32,657
+2,847
+10% +$102K 0.41% 70
2024
Q3
$1.22M Buy
29,810
+1,651
+6% +$67.5K 0.45% 62
2024
Q2
$1.08M Buy
28,159
+2,529
+10% +$106K 0.43% 66
2024
Q1
$1.1M Buy
25,630
+2,041
+9% +$84.2K 0.43% 59
2023
Q4
$874K Buy
+23,589
New +$847K 0.38% 67
2021
Q3
Sell
-9,062
Closed -$451K 135
2021
Q2
$451K Sell
9,062
-48
-0.5% -$2.31K 0.27% 88
2021
Q1
$406K Buy
9,110
+72
+0.8% +$3.27K 0.26% 93
2020
Q4
$416K Sell
9,038
-300
-3% -$13.8K 0.25% 98
2020
Q3
$439K Buy
9,338
+360
+4% +$18K 0.3% 86
2020
Q2
$457K Sell
8,978
-1,803
-17% -$92.5K 0.35% 76
2020
Q1
$511K Sell
10,781
-887
-8% -$47.3K 0.51% 55
2019
Q4
$689K Buy
+11,668
New +$649K 0.52% 43

Other funds holding GSK

Argent Advisors's GSK Position: Q1 2026 in Review

Argent Advisors reduced its GSK (GSK) stake by 2.3% in Q1 2026, selling an estimated $67.8K and leaving 53,310 shares worth $2.94M. The position accounts for 0.8% of the portfolio, ranked #35.

Argent Advisors first reported a position in GSK in Q4 2019 and has held it in 17 quarters since. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Argent Advisors held 53,310 shares of GSK worth $2.94M as of Q1 2026.
  • Argent Advisors sold 1,251 GSK shares in Q1 2026, an estimated $67.8K.
  • GSK made up 0.8% of Argent Advisors's portfolio in Q1 2026, its #35 holding.
  • Argent Advisors first reported a position in GSK in Q4 2019 and has held it in 17 quarters since.
  • 1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Argent Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.